skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

View Informa Pharma Intelligence's Pulse Report

This year, the vaccine development process has been shoved into the spotlight as groups across the globe race to get approval for a COVID-19 vaccine. A new focus on exactly what goes into vaccine development has prompted intense scrutiny from the American public on the clinical trial process. While many were ware of clinical trials before the COVID-19 pandemic, the virus has caused most Americans to pay closer attention over the past few months. Yet, this focus hasn’t resulted in increased confidence as more than
half of Americans have said they’re not comfortable taking a COVID-19 vaccine upon approval.

The goal of our Clinical Trials & the COVID-19 Vaccine Pulse Report was to examine why this may be the case, and how industry players could increase confidence.
COVID-19 Pulse report

Read also

  • Citeline

    Clinical Trials 2019 Round-up

    The clinical trial landscape continues to evolve as scientific breakthroughs and technological innovations emerge. Examine the state of Phase I–III clinical trials initiated in 2019 when you download the Annual Clinical Trials Roundup from Citeline’s Trialtrove, your trusted source for global clinical trials intelligence.

    Topics Clinical Trials

  • Citeline

    The New Normal for Clinical Trials and Planning for the Future Webinar

    Join our panel of experts as they discuss the impact of COVID-19 on clinical trials, the new normal and future pathways to get ahead. Get the latest insights and status on recent clinical trials, the emergence of virtual trials, and what you need to know for success.

    Topics Clinical Trials

  • Citeline

    Rare Congenital and Genetic Diseases Strategy Solutions

    Gain Clarity of Sight into What Comes Next with Citeline According to Informa’s Pharmaprojects, less than 3% of all rare congenital and genetic diseases have an approved therapy. Opportunities abound ­if you know the risks. Make better strategic and planning decisions with Intelligence services that give you a clear line of sight, helping you maximize clinical and commercial opportunities, navigate uncertainties, and ensure more successful outcomes. 

    Topics Diseases

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: